Three companies are now openly competing to deliver the first prescription drug whose label says, in plain language, that it extends the healthy life of a dog. The leader in mainstream coverage is Loyal, the San Francisco biotech whose LOY-002 daily tablet is the furthest along the U.S. veterinary regulatory pathway. Two other programmes — one focused on rapamycin analogues, one on senolytic combinations — are quietly running parallel trials in mid-sized breed cohorts and have not yet faced the press scrutiny that comes with a public pivotal study.

The 2026 picture is still defined by what we don't have rather than what we do. There is no published mortality readout from a placebo-controlled multi-year trial. The strongest signals so far are improvements in functional biomarkers — gait quality, owner-reported energy, frailty scores, and a handful of inflammation panels — measured at 6 and 12 months. Those signals are consistent across studies, which is why the field is taken seriously, but consistent biomarker movement is not the same thing as a dog living an extra year.

Regulators are doing something genuinely new here. The FDA's Center for Veterinary Medicine has signalled that it will accept "reasonable expectation of effectiveness" as a basis for conditional approval, which is the same legal mechanism used for novel cancer drugs in dogs. Europe's EMA is preparing a parallel guidance document for the second quarter, and several Asia-Pacific authorities have indicated they will follow whichever of the major agencies moves first. None of this guarantees a 2026 launch, but it removes the regulatory uncertainty that was the single largest unknown a year ago.

For owners, three things are worth doing now. First, make sure your dog has at least one full senior bloodwork panel on file, ideally before symptoms appear, so any future longevity intervention has a meaningful baseline to compare against. Second, settle the body-condition and dental questions — the boring foundational care that compounds with anything pharmacological that ships later. Third, decide where you want to be in the queue: every credible programme is going to oversubscribe in the first 90 days, and several will run waiting lists by region, breed, and age band.

We update this dossier whenever the worldwide scan surfaces a material change. Subscribe to the launch alert to get a single email when the picture genuinely shifts — not a weekly digest, not a marketing newsletter, just a heads-up when something concrete has moved.